What the name means
“KLOW” is “GLOW” with a K in front: the vendor blend of GHK-Cu, BPC-157 and TB-500 with a fourth research peptide, KPV, added. It is a marketing name for a vial, not a compound. Ratios are unspecified and vary by seller. The four components each have a profile on this site; the blend gets its own page because the name has become a search term in its own right, mostly attached to claims about inflammation, gut health and skin.
| Component | What it is | Human evidence | Regulatory status |
|---|---|---|---|
| KPV | Tripeptide Lys-Pro-Val — the C-terminal fragment of α-MSH | None. Anti-inflammatory effects reported in mouse colitis and skin models | Authorization not established by cited sources |
| GHK-Cu | Copper-binding tripeptide | Small topical studies on skin; none by injection | Cosmetic ingredient only |
| BPC-157 | 15-residue synthetic fragment | No randomized human efficacy trial in cited sources | Not approved; FDA barred from compounding (2023) |
| TB-500 | 7-residue thymosin β4 fragment | None for the fragment | Not approved; WADA-prohibited |
KPV: the component people know least about
KPV is the last three residues of α-melanocyte-stimulating hormone (α-MSH), a 13-residue hormone with well-established anti-inflammatory signalling through melanocortin receptors. The tripeptide retains some of that activity in cell and mouse studies — reduced inflammatory cytokine production, improvement in chemically induced colitis, and effects in skin inflammation models — apparently through a pathway that does not require the classic melanocortin receptor. That is a genuine, if small, preclinical literature. It contains no human trials, no pharmacokinetics by injection and no safety data. The KPV profile lists the primary papers.
The other three
GHK-Cu has small human studies, all topical. BPC-157 has a large rodent literature and a small human oral safety study. TB-500 is a synthetic fragment of thymosin β4 with no human data of its own. The GLOW and Wolverine guides cover these in detail, including the 2023 FDA decision barring BPC-157 from compounding and the WADA prohibitions.
Four unstudied peptides do not make one studied product
No study has examined any two of these peptides together, let alone all four. A four-component fixed-ratio product would need its own pharmacology, stability and safety work, and none has been published. The copper in GHK-Cu can catalyse oxidation of susceptible residues in co-formulated peptides, and KPV, BPC-157 and TB-500 all contain candidates. Whatever a “KLOW” vial contains after weeks in solution is not known. Independent assays of grey-market vials routinely find mislabelled or degraded content.
Legal and safety status
Health Canada has warned about unauthorized injectable peptides sold online, including products described with these ingredient names. Its warning concerns Canadian products and does not establish every jurisdiction's approval status. Check the particular regulator, product and indication. A research label does not demonstrate safety, quality or authorization, and the sources here do not establish human safety of a marketed blend.
Reading the claims responsibly
The sources cited here do not establish authorization, human efficacy or safety for the marketed blend. “Research use only” labelling does not change that. This page explains what the name refers to; it is not guidance on obtaining or using any product.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Dalmasso et al. (2008) — PepT1-mediated KPV uptake and intestinal inflammation
Cell and mouse experiments; does not establish efficacy or safety of a four-component blend in humans.
Relevant sections: KPV: the component people know least about
- Maquart et al. (1988) — GHK-Cu and collagen synthesis in fibroblast cultures
Cell-culture collagen endpoint, not a human injectable skin or hair trial.
Relevant sections: The other three
- Biçer et al. (2026) — BPC-157, TB-500 and their combination in rat Achilles tendon repair
32-rat experiment with the authors' TB-500 material; its sequence was not characterized. No added combination benefit; not human evidence.
Relevant sections: The other three · Four unstudied peptides do not make one studied product
- Health Canada (2026) — unauthorized injectable peptides bought online
Canadian safety and authorization notice for the products described. It does not establish approval status in every country.
Relevant sections: Legal and safety status
FAQ
What is the KLOW peptide?+
A vendor blend of four unapproved research peptides — KPV, GHK-Cu, BPC-157 and TB-500 — in one vial. It is not a single peptide.
What is KPV?+
The tripeptide Lys-Pro-Val, the C-terminal fragment of α-MSH. It has anti-inflammatory effects in mouse models and no human data.
KLOW vs GLOW — what is the difference?+
KLOW is GLOW (GHK-Cu, BPC-157, TB-500) plus KPV.
Is KLOW peptide approved or safe?+
Authorization not established by cited sources; no safety data for the blend exist. Vial contents in the grey market are frequently not what the label says.